Biologics is an international, peer-reviewed, open access journal on all areas of biologics derived from both novel and established biotechnologies, published quarterly online by MDPI.
  • Open Access— free for readers, with article processing charges (APC) paid by authors or their institutions.
  • Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.5 days after submission; acceptance to publication is undertaken in 8.6 days (median values for papers published in this journal in the first half of 2023).
  • Recognition of Reviewers: APC discount vouchers, optional signed peer review, and reviewer names published annually in the journal.
  • Biologics is a companion journal of JCM.
Add your e-mail address to receive forthcoming issues of this journal:
Topic in Biologics, Biology, MPs, Pathogens, Vaccines
Global Analysis of SARS-CoV-2 Serology, Part 2 Topic Editors: Ger Rijkers, Jean-Luc Murk
Deadline: 31 December 2023
Special Issue in Biologics
Novel Vaccine Technologies and Platforms to Protect from Infectious Diseases Guest Editors: Alexander Zakhartchouk, Sams Sadat
Deadline: 15 October 2023
Special Issue in Biologics
Anti-SARS-CoV-2/COVID-19 Drugs and Vaccines - Part II Guest Editors: Vasso Apostolopoulos, Majid Davidson
Deadline: 20 December 2023
Special Issue in Biologics
Aged Population and Immunocompromised Patients: Impact on SARS-CoV-2 Variants and Treatment Outcomes Guest Editors: Vasso Apostolopoulos, Vivek P. Chavda, Mahesh Chhabria
Deadline: 31 December 2023
Back to TopTop